[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100438641":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":36,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":7,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":7,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":19,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"BostonGene","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Nathan Fowler","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+1-617-658-4545","nathan.fowler@bostongene.com",[18],{"facility":5,"status":19,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"RECRUITING","Waltham","Massachusetts","02453","United States","US",{"type":26,"coordinates":27},"Point",[28,29],-71.23561,42.37649,{"lat":29,"lon":28},[32],{"name":33,"role":14,"phone":34,"phoneExt":7,"email":35},"Krystle Nomie, PhD","617-658-4545","krystle.nomie@bostongene.com",{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100438641","bostongene-integrated-genomic-registry-bigr-100438641",false,"NCT04991922","BostonGene-Integrated Genomic Registry (BIGR)","BostonGene-Integrated Genomic Registry Study","Inclusion Criteria:\n\n1. Suspected or confirmed malignancy\n2. Planned comprehensive genomic (\\> 100 genes) and\u002For molecular analysis; or genomic and\u002For molecular data available from prior sequencing\n3. Baseline demographics and treatment information available\n4. Willingness for future contact by BIRG study personnel to provide information regarding associated cancer outcomes and treatment.\n5. Signed informed consent to participate in the study.\n6. Living in the United States at the time of enrollment\n\nExclusion Criteria:\n\nLife expectancy \\\u003C 3 months","ALL","18 Years",{"count":48,"type":49},100000,"ESTIMATED","OBSERVATIONAL","The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to improve future clinical outcomes across cancer types",[53],"Malignancy",[55,56,57,58,59,60,61,62],"cancer","precision medicine","WES","RNA-seq","immuno-therapy","genomic","transcriptomic","multiomic","2024-02-06",{"date":65,"type":66},"2024-02-07","ACTUAL",{"date":68,"type":66},"2021-07-01",{"date":70,"type":49},"2036-07-01",{"name":5,"class":6},1]